Genzyme's Once-Daily, Oral AUBAGIO Approved in Australia
Genzyme, a Sanofi company, (NYSE: SNY) announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO^® (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). The TGA approval will enable health professionals to prescribe AUBAGIO 14 mg in Australia, which is now the second country to gain marketing authorization for the treatment, following FDA approval in September.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.